Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers are considered the standard of care for treatment of cardiovascular disease and chronic kidney disease. Combination therapy with both angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers effectively inhibits the renin-angiotensin system as well as potentiates the vasodilatory effects of bradykinin. It has been advocated that this dual blockade approach theoretically should result in improved clinical outcomes in both cardiovascular disease and chronic kidney disease. Clinical trial evidence for the use of combination therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in cardiovascular disease has provided conflicting results in hypertension, congestive heart failure, and ischemic heart disease. Clinical trial evidence to support combination therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease has largely been based on proteinuria reduction as a surrogate marker for clinically meaningful outcomes. Recent large-scale randomized clinical trials have not been able to validate protection in halting progression in chronic kidney disease with a dual blockade approach. This review serves as an appraisal on the clinical evidence of combination angiotensin-converting enzyme inhibition and angiotensin II receptor blockade in both cardiovascular disease and chronic kidney disease.
Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers are considered the standard of care for treatment of cardiovascular disease and chronic kidney disease. Combination therapy with both angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers effectively inhibits the renin-angiotensin system as well as potentiates the vasodilatory effects of bradykinin. It has been advocated that this dual blockade approach theoretically should result in improved clinical outcomes in both cardiovascular disease and chronic kidney disease. Clinical trial evidence for the use of combination therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in cardiovascular disease has provided conflicting results in hypertension, congestive heart failure, and ischemic heart disease. Clinical trial evidence to support combination therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease has largely been based on proteinuria reduction as a surrogate marker for clinically meaningful outcomes. Recent large-scale randomized clinical trials have not been able to validate protection in halting progression in chronic kidney disease with a dual blockade approach. This review serves as an appraisal on the clinical evidence of combination angiotensin-converting enzyme inhibition and angiotensin II receptor blockade in both cardiovascular disease and chronic kidney disease. A wealth of research and publications has ensued in the last few decades describing the beneficial effects of inhibition of the renin-angiotensin system in cardiovascular disease and chronic kidney disease (CKD). Angiotensin-converting enzyme (ACE) inhibition has improved survival and reduced morbidity in hypertension, congestive heart failure (CHF), acute myocardial infarction, and halts progression in CKD. Angiotensin receptor blockers (ARBs) have been shown to be equally efficacious to ACE inhibition in both cardiovascular disease and CKD populations. ACE inhibitors or ARBs are considered the standard of care for treatment of hypertension in diabetes mellitus and CKD, reducing proteinuria and CKD progression, and improving outcomes in CHF and acute myocardial infarction. As both of these classes of medications were used in both cardiovascular disease and CKD, the theory that 'more is better' ensued and dual blockade of the renin-angiotensin system was advocated by many leading physicians. This review serves as an appraisal on the clinical evidence of combination ACE inhibition and angiotensin receptor blockade (combination therapy) in both cardiovascular disease and CKD.
The belief of impurities in the blood causing hypertension dates back well over 2000 years in ancient Egypt and Asia. The association between hypertension, cardiovascular disease, and kidney disease was first made by Richard Bright 1 in 1836. Modern day hypertension was described by Frederick Mahomed 2 in 1872 with primitive sphygmography. Development of the blood pressure cuff by Riva-Rocci 3 in 1896 and auscultation of blood flow with such a device by Nikolai Korotkoff 4 in 1905 pioneered research into the physiological mechanisms of hypertension.
The renin-angiotensin system was first described by Tigerstedt and Bergman 5 in 1898, with the observation that infusion of a substance termed 'renin' isolated from rabbit kidneys induced hypertension. The importance of the kidney in modulating hypertension was shown by the work of Harry Goldblatt et al. 6 in 1934 who demonstrated that renal ischemia resulted in an animal model of hypertension. This model, termed 'Goldblatt hypertension', supported Tigerstedt and Bergman's previous description of a vasopressor substance released into the renal vein during periods of renal ischemia. Frey and Krant discovered kallirein in 1926, 7 and parallel groups of investigations led by Eduardo Braun-Menendez and colleagues 8 in Argentina and by Irving Page and colleagues 9 in Indianapolis in the 1930-1940s demonstrated the pathway of renin activation to 'hypertensin' and 'angiotonin' by a renin activator. In 1956, Skeggs et al. 10 discovered ACE and by 1961 the terminology of 'hypertensin' and 'angiotonin' was changed to angiotensinogen as the renin substrate and angiotensin as the active metabolite. 11 The renin-angiotensin system was further characterized by efforts made by John Vane, Kevin Ng, Sergio Ferreira, Ervin Erdös, and Mick Bakhle and others who described conversion of angiotensin I to angiotensin II in the pulmonary circulation through ACE with bradykinin inactivation. 12, 13 A bradykinin-potentiating factor isolated from pit viper venom (Bothrops jararac) resulted in ACE inhibition and identified a novel mechanism in the treatment of hypertension. 12 Collaboration with research scientists at Squibb and other experts in the field at that time led to the formulation of the first oral ACE inhibitor, captopril. Under the direction of John Laragh and colleagues, 14 a clinical trial for the treatment of hypertension with captopril was conducted in 1978 and led to Food and Drug Administration (FDA) approval of captopril for treatment of hypertension in 1981. Drug development in the discovery of angiotensin II receptor blockers and direct renin inhibitors occurred during the mid 1980s, but was limited by the use of peptide compounds that had a short half-life and were not orally bioavailable. It was not until 1982 that a group of scientists at DuPont laboratories reviewed a US patent that described imidazole derivates that demonstrated angiotensin II receptor-blocking activity. 15 Such imidazole derivates were highly selective for the angiotensin II receptor, but required massive doses for potency that the possibility of drug development was abandoned in several laboratories. It was not until a molecular change with the addition of a tetrazole group that losartan was developed and ultimately approved as the first ARB by the FDA in 1995. Finally, aliskiren, the first oral direct inhibitor of renin, was developed and approved for treatment of primary hypertension by the FDA in 2007.
DUAL BLOCKADE OF THE RENIN-ANGIOTENSIN SYSTEM AND CARDIOVASCULAR DISEASE Rationale
There are good theoretical reasons why complete inhibition of the renin-angiotensin system should result in improved clinical outcomes in cardiovascular disease. In addition to blood pressure regulation and cardiac remodeling, angiotensin has been implicated in inflammation, oxidative stress, atherosclerosis, and has proliferative effects through the AT 2 receptor. [16] [17] [18] [19] ACE inhibitors block the conversion of angiotensin I to angiotensin II and additionally inhibit kininase II, potentiating the beneficial vasodilatory effects of bradykinin and nitric oxide resulting in blood pressure lowering. [16] [17] [18] However, with ACE inhibitors alone, there is incomplete inhibition of the renin-angiotensin system because of 'angiotensin escape' , which refers to production of angiotensin II through non-ACE pathways. 17 Therefore, combination therapy with inhibition of angiotensin II formation through ACE with ACE inhibitors and blockade of angiotensin II binding to the AT receptors with ARBs provides a more complete blockade of the angiotensin effects. One caveat in combination therapy is that ACE inhibitors and ARBs increase renin stimulation. Renin has been associated with increased risk for myocardial infarction and stroke, 20 and therefore combination therapy is not 'complete' inhibition of the renin-angiotensin system (Figure 1 ). The following serves as a review of the clinical evidence for combination therapy in the treatment of hypertension, CHF, and ischemic heart disease.
Hypertension
One of the early treatment trials in hypertension with combination therapy was published in 2000 by Azizi et al., 21 who reported that combination of losartan and enalapril compared with monotherapy with either agent alone had a greater diastolic blood pressure lowering at study clinic visits but did not show a significant difference in the 24-h mean ambulatory blood pressure. A series of other trials of combination therapy for hypertension were published between 2000 and 2005 but were limited by small sample sizes, lack of pre-defined hard clinical end points, use of nongeneralizable subject populations, short durations of followup, or suboptimal drug dosing regimens. [22] [23] [24] In 2001, Weir et al. 25 reported in 6465 hypertensive subjects that the most significant blood pressure-lowering effects were seen with candesartan and diuretics, followed by candesartan and calcium antagonists, candesartan and b-blockers, and the least effective combination was with candesartan and ACE inhibitors. This trial confirmed the results of the AURA (Atacand Under Real-life Aspects) study that candesartan was an effective anti-hypertensive agent in primary hypertension; however, when added on to other classes of antihypertensive medications, combination of ACE inhibitors and ARBs had the weakest effect. 26 The AMAZE (A Multicenter trial using Atacand and Zestril versus zestril to Evaluate the effects on lowering blood pressure) trials included two randomized, multi-centered, double-blind controlled investigations comparing the combination of lisinopril and candesartan versus maximizing the dose of lisinopril alone. 27 The results of the studies provided conflicting data with one of the cohorts demonstrating that combination therapy was superior, whereas the second cohort could not corroborate the same results.
A meta-analysis published in 2005 by Doulton et al. 28 summarized the evidence of combination therapy as compared with monotherapy for the treatment of hypertension. A series of 14 publications met the author's inclusion criteria of hypertensive subjects, having blood pressure control as an outcome measure and requiring that the trial design include randomization. The results showed that blood pressure reductions were modest with combination therapy as compared with monotherapy and achieved statistical significance; however, the authors concluded that the impact on clinical outcomes was likely to be minor and therefore were unable to recommend combination therapy over other drug regimens.
The ONTARGET (The ONgoing Telmisartan Alone and in combination with Ramipril Global End point Trial) trial was a landmark trial of combination therapy in high-risk subjects with cardiovascular disease or diabetes mellitus without CHF. 29 A total of 25,620 subjects underwent randomization into three double-blind treatment arms of ramipril (10 mg daily), telmisartan (80 mg daily), or the combination of telmisartan and ramipril daily. The primary outcomes of this investigation were twofold: first to determine non-inferiority of telmisartan compared with ramipril and second to investigate whether combination therapy was superior to ramipril alone in a composite end point of death from cardiovascular causes, myocardial infarction, stroke, or hospitalization for heart failure. Approximately 69% of those enrolled in the study had baseline primary hypertension. All three treatment groups demonstrated effective lowering of blood pressure that was persistent throughout the study, and in the combination group, there was a greater reduction in blood pressure as compared with the single treatment arms. Surprisingly, the beneficial effect of blood pressure lowering did not result in greater protection that has been shown in other cardiovascular studies. For the composite outcomes of death from cardiovascular causes, myocardial infarction, stroke, or hospitalization for heart failure, combination therapy did not demonstrate a significant benefit over monotherapy (relative risk 0.98 (0.90, 1.07)). On review of the adverse events, combination therapy was associated with significantly greater episodes of hypotensive symptoms, syncopal events, diarrhea, kidney impairment, and hyperkalemia. The increased risk of these adverse events and the lack of benefit on the clinical composite outcomes of this study led investigators to conclude that combination therapy is not warranted for this patient population. Criticisms of this study validly point out that using combination therapy for 30% of the study population that was normotensive contributed to excess syncopal and hypotensive events and likely increased the cardiovascular events in this trial. This is in keeping with previous studies, which have suggested that reducing blood pressure is associated with a J-curve in which lower blood pressures are associated with increased cardiovascular events. 30, 31 In all practically, enrolling normotensive subjects in a dual anti-hypertensive clinical trial targeted at drug dosing rather than at blood pressure should have raised concern. Despite criticisms of the trial design, the results of the ONTARGET trial resulted in leading investigators along with the Canadian Hypertensive Education Program and the Canadian Heart and Stroke Foundation in 2009 to strongly advise discontinuation of combination therapy in the treatment of hypertensive patients. 32, 33 Congestive heart failure If there is a lack of superiority established thus far with the use of combination therapy in hypertension (Table 1 ) or in a high-risk cardiovascular population, are there other cardiovascular disease states such as CHF or myocardial infarction in which combination therapy may be effective? Several clinical trials have been performed to address these populations, including RESOLVD (Randomized Evaluation of Strategies for Left Ventricular Dysfunction), Val-HeFT (VALsartan Heart Failure Trial), and the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) studies. [34] [35] [36] [37] [38] RESOLVD was a pilot study published in 1999 to study the effects of candesartan and enalapril as compared with candesartan alone or enalapril alone in symptomatic subjects with NYHA (New York Heart Association) Class II-IV CHF with a reduced ejection fraction. 31 The authors concluded that there was a benefit of combination therapy on left ventricular remodeling based on measurements of left ventricular systolic and diastolic volumes but lacked meaningful clinical end points in the study. The Val-HeFT trial was a multi-centered randomized double-blind placebo-controlled trial of 5010 subjects with CHF as defined by NYHA Class II-IV with reduced ejection fraction. 32 Valsartan was compared with standard CHF therapy, with the majority of subjects receiving ACE inhibitors. The results revealed that there was no significant benefit with valsartan for mortality (relative risk 1.02 (0.88, 1.18)); however, a benefit was seen in the composite end points of mortality and morbidity (relative risk 0.87 (0.77, 0.97)). Further evidence suggested benefit for the use of combination therapy for treatment of CHF with the publication of the CHARM studies ( Table 2 ). The CHARM studies were a series of three clinical trials evaluating the effects of candesartan on subjects with CHF intolerant to ACE inhibitors (CHARM-Alternative trial), 36 on subjects currently on ACE inhibitors with a preserved ejection fraction (CHARM-Preserved trial), 37 and on subjects currently on ACE inhibitors with a reduced ejection fraction (CHARM-Added trial). 38 On the basis of these study results, Practice Guidelines from both Europe and the United States suggest recommendations for the use of combination therapy in CHF. The European guidelines recommend that an ARB is indicated in CHF with ejection fraction p40% if there are CHF symptoms on optimal standard-of-care therapy with ACE inhibitors (class of recommendation 1, level of evidence A). 39 The United States guidelines are slightly different, and in the most recent 2009 update, recommendations suggest that an ARB added to an ACE inhibitor may be considered in symptomatic CHF but should not be used with other aldosterone antagonists (class II recommendation, level of evidence B). 40 The difference in the two guidelines focused on the strength of the evidence for a lack of all-cause mortality benefit demonstrated in the combination therapy treatment groups in the aforementioned clinical trials. [35] [36] [37] [38] 
Ischemic heart disease
Clinical trials examining the efficacy of combination therapy as compared with monotherapy are limited in subjects with ischemic heart disease. In 2003, the VALIANT (VALsartan in Acute myocardial INfarction) trial showed that in subjects with acute myocardial infarction with left ventricular dysfunction, there was no difference in mortality or in the secondary end points of death by cardiovascular causes, recurrent myocardial infarction, or hospitalization for CHF in the combination of valsartan and captopril as compared with captopril alone. 41 There is a paucity of clinical trials examining the effects of combination therapy for myocardial infarction with preserved left ventricular function, and in a recent systematic review, the only clinical trial that was able to be included was the ONTARGET trial. 29, 42 The authors reiterated the previously published ONTARGET study conclusions that there was no benefit for combination therapy on reducing the risk of mortality or other cardiovascular outcomes for myocardial infarction with preserved ejection fraction and that there may be harm with the increased risk of adverse events in the combination therapy group.
Summary of the evidence for dual blockade of the renin-angiotensin system and cardiovascular disease At this time, there is no compelling evidence to recommend the use of combination therapy simply for the treatment of hypertension. Combination therapy does not change allcause mortality in CHF; however, clinical evidence supports that combination therapy may be considered for those with symptomatic CHF with reduced ejection fraction to reduce cardiovascular death and hospitalizations. There is no benefit of combination therapy for acute myocardial infarction with reduced or preserved left ventricular function.
DUAL BLOCKADE OF THE RENIN-ANGIOTENSIN SYSTEM AND CKD Rationale
Blockade of the renin-angiotensin system with either ACE inhibitors or ARBs has been shown in numerous studies to improve outcomes in CKD beyond their effects on lowering systemic blood pressure. Although the precise mechanism is not known, the additional beneficial effects have been attributed to preferentially lowering intra-glomerular pressure through effects on the efferent arteriole resulting in reduction in proteinuria, blocking of mediators of inflammation, inhibiting oxidative stress, and eventually preventing fibrosis and renal scarring. [43] [44] [45] Dual blockade of the renin-angiotensin system with ACE inhibitors and ARBs has been postulated to improve clinical outcomes in CKD superior to monotherapy by greater reduction in proteinuria, which is a risk factor for CKD progression and end-stage kidney disease (ESKD). The remainder of this review focuses on the clinical evidence of combination therapy in both diabetic and non-diabetic kidney disease.
Diabetic kidney disease
Diabetes mellitus is the leading cause of CKD and ESKD in the United States. Numerous randomized clinical trials have demonstrated the benefit of ACE inhibitors or ARBs in albuminuria reduction and in slowing CKD progression in diabetic nephropathy. [46] [47] [48] [49] [50] The concept of dual blockade of the renin-angiotensin system with combination therapy was advanced in the late 1990s and early 2000s, with several small clinical trials suggesting renoprotection in diabetics with both microalbuminuria and overt nephropathy. One of the largest of these early clinical trials was performed by Mogensen et al. 51 with the publication of the CALM (The Candesartan And Lisinopril Microalbuminuria) study. At 12 weeks, combination therapy with candesartan and lisinopril was more effective than monotherapy in blood pressure lowering and reducing albuminuria. However, this trial was criticized by the use of suboptimal drug doses that were not applicable to clinical practice. In a subsequent trial, Rossing et al. 52 added candesartan to maximal doses of an ACE inhibitor in type 2 diabetic subjects and demonstrated that there was additional blood pressure lowering and proteinuria reduction with combination therapy as compared with monotherapy. An insignificant decline in glomerular filtration rate (GFR) was also noted in the combination treatment group. Although this trial used drug dosing that was more applicable to clinical practice, it was still limited by a small sample size of 20 subjects and short duration of 8 weeks follow-up. Similar results have been demonstrated for combination therapy in type 1 diabetics. In a small clinical trial of 20 subjects, the combination of benazepril and valsartan was more effective in reducing blood pressure and albuminuria at 8 weeks compared with monotherapy and confirmed the CALM study results. 53 However, it is noteworthy that there was a significant decline in the GFR in the combination group of 10 ml/min per 1.73 m 2 as compared with the monotherapy groups that was reversible once therapy was discontinued. These studies were again criticized for using suboptimal dosing regimens for both ACE inhibitors and ARBs. Jacobsen et al. 54 reported results of a small clinical trial in type 1 diabetics with hypertension and nephropathy, who had a maximum dose of irbesartan added to maximal doses of enalapril. At 8 weeks, there were significant reductions in blood pressure and in proteinuria excretion in the combination therapy group than in the enalapril only group; however, long-term follow-up was not reported.
A meta-analysis of the clinical trials for combination therapy in diabetic subjects was published in 2007 by Jennings et al. 55 This analysis included 10 trials with 156 subjects receiving combination therapy. The results demonstrated that combination therapy was more effective in reducing proteinuria; however, there was a decrease in estimated GFR (eGFR) and a trend toward increased creatinine in the combination group. The authors concluded that recommendation for widespread use of combination therapy for diabetic nephropathy is limited by using proteinuria as a surrogate marker for kidney outcomes, and lack of hard clinical end points such as morality or cardiovascular events in the active treatment groups. In attempts to address issues of short follow-up times and small sample sizes, the CALM II trial and the IMPROVE (Irbesartan in the Management of PRoteinuric patients at high risk for Vascular Events) trial were performed to examine the effects of combination therapy on albuminuria reduction and blood pressure control over a longer treatment time 56 and in larger populations. 57 In the CALM II trial, the combination of candesartan and lisinopril was compared with uptitration of lisinopril alone in hypertensive diabetic subjects. In contrast to the CALM study, at the end of 12 months, there was no significant difference in blood pressure lowering or albuminuria excretion in the combination group as compared with lisinopril alone. In the IMPROVE trial, 405 hypertensive subjects with microalbuminuria at high cardiovascular risk previously on ACE inhibitors were randomized to combination therapy with irbesartan and ramipril versus ramipril alone. No significant difference was demonstrated in the combination therapy as compared with ramipril, despite lower blood pressures in the combination arm. In a subanalysis of those with albumin excretion rates of X200 mg/min, there was a trend toward benefit with combination therapy as compared with ramipril, but this analysis was significantly underpowered to adequately address the use of combination therapy in macroalbuminuria. These results mirrored previous hypertension studies that combination therapy has not been proven to be superior to maximal doses of monotherapy, 27 and raise the question that if blood pressure is similar in the treatment groups, is there a demonstrable renoprotective effect unique to ACE inhibitors and ARBs in CKD? This was brought into question with the publication of a meta-analysis by Casas et al., 58 in 2005, who reported that there was no added benefit of ACE inhibitors or ARBs in doubling of the serum creatinine or progression to ESKD in diabetic subjects compared with other antihypertensive medications independent of their blood pressure-lowering effects.
Despite the lack of supporting clinical evidence of benefit with clinically meaningful outcomes, the use of combination therapy for diabetic kidney disease became a widespread practice among many nephrologists and other treating physicians in the community. Concerns regarding the safety of combination therapy arose with the publication of the ONTARGET study 29 specifically with regard to kidney outcomes. 59 Pre-specified analyses of the ONTARGET trial were performed to determine the effects of combination therapy on a primary composite outcome of dialysis, doubling of serum creatinine, or death, and second by changes in surrogate markers of kidney disease by decline in eGFR and change in albuminuria as measured by urinary albumin-to-creatinine ratios. Despite a reduction in albuminuria, there was an increased number of primary events with combination therapy (hazard ratio 1.09 (1.01, 1.18) ). Combination therapy also increased the risk for dialysis or doubling of serum creatinine (hazard ratio 1.24 (1.01, 1.51) ). The authors concluded that there was no benefit of combination therapy on kidney outcomes, and in fact, combination therapy led to overall harm. The results of this trial led to widespread criticisms of the study design and flaws in the interpretation of the results. [60] [61] [62] Such criticisms include a lack of standardization of creatinine, single measurements of both creatinine and urinary albumin-tocreatinine ratios at study visits, and the use of eGFR based on the Modification of Diet in Renal Disease study equation that is not validated in populations with eGFR 460 ml/min per 1.73 m 2 or in older subjects that were included in this trial. 63, 64 Moreover, the early decline in eGFR in combination therapy was an anticipated hemodynamic effect that has been demonstrated in other clinical trials, 65 and if taken into consideration in the statistical analysis, then there was no significant difference in eGFR decline with combination therapy as compared with monotherapy. In addition, criticisms accurately state that the need for dialysis was largely for acute dialysis and not for progression to ESKD. If acute dialysis was excluded from study analyses, then there was no difference in combination therapy as compared with monotherapy. However, it should be noted that although acute dialysis should not be included as events for dialysis that implies ESKD, acute kidney injury requiring dialysis is not benign. Acute kidney injury is associated with significant morbidity and mortality and even if kidney function recovers, acute kidney injury is one of the greatest risk factors for the development of CKD and progression to ESKD especially in an elderly population. 66 Therefore, any dialysis places an individual at risk, and exclusion of these events in attempts to justify the use of combination therapy for CKD needs to be carefully considered. If one interprets the ONTARGET trial with the flaws and criticisms for kidney outcomes, then the best interpretation is that there is no additional benefit with combination therapy as compared with monotherapy in high-risk cardiovascular and diabetic subjects.
Another factor to consider is the generalizability of the ONTARGET trial to the diabetic population. Only 4% of the diabetics enrolled in this trial had macroalbuminuria, and evidence has suggested that this high-risk population is the most likely to derive benefit from combination therapy. Clinical trial evidence is lacking at this time to fully answer how best to manage diabetics with overt nephropathy. There is some evidence that suggests that in a small cohort of patients with nephrotic range proteinuria, targeted treatment of proteinuria is beneficial. Ruggenenti et al. published their experience using 'remission clinics' in the treatment of CKD. In this cohort, one-third of the subjects with nephrotic range proteinuria were diabetic and were compared with matched historical controls of therapy targeted at blood pressure. 67 The remission clinics initiated therapy with ramipril, then losartan, and finally verapamil titrated to maximal doses to reduce proteinuria excretion to o0.3 g/day. When analyzing diabetic subjects as compared with non-diabetics, active remission clinic treatment reduced 24 h proteinuria excretion by 50%, but only a small percentage of diabetics achieved remission of o0.3 g/day. In addition, diabetics in remission clinics did not demonstrate protection in decline in eGFR as did non-diabetic subjects, and there was no benefit in diabetic subjects in the projection of reaching ESKD. Acceptable goal blood pressures were not achieved in diabetic subjects, and thus may have influenced the study results with this targeted proteinuria approach.
If one considers ONTARGET a failure for combination therapy acknowledging the criticisms, then why did it fail? Was the perception of benefit of combination therapy brought on by our interpretation of previous small, underpowered, clinical trials in which proteinuria reduction was used as a surrogate marker for CKD outcomes? There have been numerous occasions in which a surrogate marker of a disease does not correlate with clinical benefit especially in cardiovascular disease trials. 68, 69 At present, the FDA will only accept hard clinical end points for drug approval for the treatment of CKD, which includes the need for dialysis or kidney transplantation, doubling of serum creatinine, cardiovascular disease events, or death. Proteinuria reduction is not accepted at this time as a valid surrogate marker for CKD progression. In addition, any clinical trial of CKD using microalbuminuria as a surrogate marker of nephropathy is now in question with evidence to suggest that microalbuminuria may be considered as a marker of endothelial dysfunction rather than nephropathy, there is a lack of correlation for reduction in microalbuminuria and clinical outcomes in progressive kidney failure, there is spontaneous resolution of microalbuminuria in up to one-third of patients, and finally, microalbuminuria is markedly variable in patients on repeated measurements. [70] [71] [72] In 2008, the National Kidney Foundation and the FDA led a scientific workshop entitled 'Proteinuria as a Surrogate Outcome in Chronic Kidney Disease' . 73 The charge of the workshop was to address three areas: '1. the importance of proteinuria in CKD, 2. evaluation of surrogacy in clinical trials, and 3. evaluation of change in proteinuria as a surrogate outcome in kidney disease progression in 3 broad clinical areas: early diabetic kidney disease, nephrotic syndrome, and disease with mild to moderate proteinuria'. 73 The conclusions of the scientific panel at this workshop was that there is insufficient evidence that proteinuria reduction correlates with outcomes in CKD and should not be used as a primary end point in clinical treatment trials for early diabetic nephropathy. There was support for the use of proteinuria reduction as a surrogate outcome in nephrotic syndromes especially if remission is achieved as this has been reliably associated with improved CKD outcomes in past studies. Targeted proteinuria reduction in kidney diseases with mild-to-moderate proteinuria may be a viable option for surrogacy for CKD outcomes, but the evidence for this approach is not as strong as in nephrotic syndromes. There are currently three ongoing large randomized controlled treatment trials and include the NEPHRON-D study (Combination ARBs and ACE inhibitor for the treatment of diabetic nephropathy: NCT00555217), 74 the VALID trial (Preventing ESRD in Overt Nephropathy of Type 2 Diabetes: NCT00494715) (http://clinicaltrials.gov/ct2/ show/study/NCT00494715), and the ALTITUDE (Aliskiren in Type 2 Diabetes using cardio-renal end points: NCT00549757) trial 75 (Table 3) . Results of these trials will likely provide further insights into the role of combination therapy in diabetic nephropathy.
Non-diabetic kidney disease
Non-diabetic kidney disease is believed to be a different entity as compared with diabetic kidney disease and may correspond with diseases that are more apt to respond to combination therapy. Several small clinical trials have demonstrated the benefit of proteinuria reduction and blood pressure lowering with combination therapy in IgA nephropathy 76, 77 and in primary glomerular diseases. 78, 79 Further clinical evidence for the benefit of combination therapy in non-diabetic kidney disease occurred in 2003 with the publication of the COOPERATE (Combination treatment of angiotensin receptor blocker and angiotensin converting enzyme inhibitor in non-diabetic renal disease) study. 80 The COOPERATE study was designed to evaluate the efficacy of combination therapy with trandolapril and losartan as compared with monotherapy alone, and the authors concluded that combination therapy was superior to monotherapy by reducing CKD progression measured by doubling of the serum creatinine or ESKD. However, in 2006, the COOPERATE trial study results came into question by a letter to the Editor in the American Journal of Nephrology by Anil Bidani with regard to blood pressure reporting, 81 and additionally in preparation for a meta-analysis of combination therapy in CKD, Kunz et al. 82 submitted a letter of warning to The Lancet that suggested that further investigation should be performed to validate the previously published COOPERATE trial results. The Lancet responded to the letter of warning and in 2008 retracted the COOPERATE trial after investigation concluded that the scientific merits of the study followed gross misconduct. After retraction of the COOPERATE trial, two subsequent meta-analysis studies were published examining the effects of combination therapy in CKD. 83, 84 Both meta-analyses demonstrated benefit in proteinuria reduction with combination therapy; however, the inclusion of the trials was limited by small sample sizes, short-term follow-up, lack of demonstrable benefit for meaningful clinical end points such as mortality, progression of CKD, or ESKD, and the authors concluded that clinical evidence is lacking to support the use of combination therapy in the treatment of CKD. In contrast to the results published in the meta-analyses for CKD, Ruggenenti et al. 67 have demonstrated dramatic results with a targeted proteinuria reduction approach with combination therapy in their remission clinics for non-diabetic kidney disease. Approximately 30% of the non-diabetic subjects achieved remission proteinuria of p0.3 g/day. There was a significant reduction in the projection to ESKD in the subject's lifetime from 72 to 28%, and the projected time to reach ESKD increased from 8 years to 29 years. Perhaps targeting proteinuria rather than blood pressure is an optimal approach in the management of high-risk CKD.
Future trials may be able to further provide us with recommendations for combination therapy in non-diabetic CKD. The HALT PKD (HALT Progression of Polycystic Kidney Disease: NCT00283686) trial is evaluating the effect of the combination of lisinopril and telmisartan compared with lisinopril alone in polycystic kidney disease, with outcomes measured by change in total kidney volume by abdominal magnetic resonance imaging for those with eGFR 460 ml/min per 1.73 m 2 , or time to reach 50% reduction in baseline eGFR, ESKD, or death for those with eGFR 25-60 ml/min per 1.73 m 2 (ref. 85) . The LIRICO (Long-term Impact of RAS Inhibition on Cardiorenal Outcomes) trial is designed to evaluate the effects of combination therapy on high-risk subjects with microalbuminuria with a primary composite outcome of cardiovascular death, coronary hearty disease, nonfatal stroke, hospitalization for a cardiovascular event. 86 Summary of the evidence for dual blockade of the renin-angiotensin system and CKD Large-scale randomized controlled outcome trials thus far have failed to demonstrate superiority for combination therapy for halting progression of CKD. An argument should be made that targeting proteinuria rather than blood pressure and using supra-therapeutic dosing regimens may have an advantage over our current practice patterns for combination therapy in CKD. 67, [87] [88] [89] 
DIRECT RENIN INHIBITION COMBINED WITH ACE INHIBITORS OR ARBs
As stated earlier, combination therapy does not result in complete inhibition of the renin-angiotensin system. Renin is a significant risk factor for cardiovascular disease and kidney injury, 20, 90 and plasma renin activity increases with ACE inhibitor and ARB use. It may be that this 'incomplete' blockade of the renin-angiotensin system with combination therapy has led to the lack of benefit seen thus far in cardiovascular disease and CKD trials. After approval in 2007, clinical trials were developed to study the effects of aliskiren in combination with either ACE inhibitors or ARBs in cardiovascular disease and CKD. Recently, the results of the ASPIRE (Aliskiren Study in Post-MI patients to Reduce rEmodeling) trial were presented at the American College of Cardiology in 2010. In this trial, aliskiren was added to either ACE inhibitors or ARBs in subjects with acute myocardial infarction and left ventricular dysfunction. The investigators cited that there was no benefit of aliskiren on cardiovascular death, recurrent myocardial infarction, stroke, and resuscitated sudden death. 91 Little evidence is available for direct renin inhibition with CHF; however, an ongoing trial, the ATMOSPHERE trial (Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbi-mortality in Patients With Chronic Heart Failure: NCT00853658), is evaluating the efficacy and safety of aliskiren and aliskiren/ enalapril combination in patients with chronic heart failure with a primary outcome of cardiovascular death or CHF hospitalization (http://clinicaltrials.gov/ct2/show/ NCT00853658). Similar to previous CKD trials, the AVOID (Aliskiren in the Evaluation of Proteinuria in Diabetes) trial has demonstrated efficacy for aliskiren on proteinuria reduction in combination with losartan for diabetic nephropathy over a short time period but lacked clinical end points. 92 The ongoing ALTITUDE trial 75 will be provide further insights into the role of aliskiren in the treatment of diabetic nephropathy.
CURRENT RECOMMENDATIONS AND FUTURE DIRECTIONS FOR THE USE OF COMBINATION THERAPY
On the basis of evidence to date, we have summarized current recommendations in Table 4 (http://www. uspreventiveservicestaskforce.org/3rduspstf/ratings.htm). We believe that proteinuria remission is a reasonable target for those with CKD and those with macroalbuminuria should be considered a high-risk population that may benefit from such an approach until further randomized clinical trial evidence with meaningful clinical outcomes is available to guide our practice. Importantly, it should be emphasized that there have been no adequately powered completed clinical trials or ongoing clinical trials that will fully address cardiovascular outcomes with combination therapy with ACE inhibitors and angiotensin II receptor blockers in CKD.
At present, development of novel therapies for halting progression in CKD requires extensive resources and large-scale randomized clinical trials lasting several years. As a result, proteinuria has often been used as a surrogate marker to indicate potentially beneficial effects in halting CKD progression. However, several examples exist that have demonstrated that reduction in proteinuria does not always lead to long-term benefit in halting progression of kidney disease. In contrast, there are other examples wherein therapies had no effect on proteinuria but were effective in halting progression in CKD. [93] [94] [95] Thus, we are in need of other biomarkers for CKD progression that are easy to measure and serve as acceptable surrogates for clinical efficacy both to the regulatory agencies and to the nephrology community. Recent studies have indicated that the urinary biomarkers for acute kidney injury, namely neutrophil gelatinase-associated lipocalin, kidney injury molecule, and liver fatty acid-binding protein may also be useful to predict progression in CKD. [96] [97] [98] [99] [100] [101] There is a need to urgently obtain robust data, which would evaluate the utility of the known and yet undiscovered biomarkers for predicting CKD progression that would serve as acceptable surrogates for drug development rather than awaiting the results of largescale randomized clinical trials that in the recent past have not provided us with solid evidence to change our current practice in the treatment of progressive CKD. Level of evidence C: Limited clinical evidence that supports recommendation for combination therapy but favors use while awaiting further clinical trial evidence Level of evidence based on the US Preventive Services Task Force. Level A: good scientific evidence suggests that the benefits of the clinical service substantially outweigh the potential risks. Clinicians should discuss the service with eligible patients. Level B: at least fair scientific evidence suggests that the benefits of the clinical service outweigh the potential risks. Clinicians should discuss the service with eligible patients. Level C: at least fair scientific evidence suggests that there are benefits provided by the clinical service, but the balance between benefits and risks are too close for making general recommendations. Clinicians need not offer it unless there are individual considerations. Level D: at least fair scientific evidence suggests that the risks of the clinical service outweigh potential benefits. Clinicians should not routinely offer the service to asymptomatic patients. Level I: Scientific evidence is lacking, of poor quality, or conflicting, such that the risk versus benefit balance cannot be assessed. Clinicians should help patients understand the uncertainty surrounding the clinical service.
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